Prognostic factors for survival in patients with metastatic lung adenocarcinoma: An analysis of the SEER database.

BACKGROUND: Lung adenocarcinoma (ADC) is the main cause of death related to lung cancer. The aim of this study was to identify poor prognostic factors for overall survival (OS) in patients with stage IV lung ADC in real-world clinical practice. METHODS: Patients were selected from the Surveillance E...

Descripción completa

Detalles Bibliográficos
Autores: Campos-Balea B, de Castro Carpeño J, Massutí B, Vicente-Baz D, Pérez Parente D, Ruiz-Gracia P, Crama L, Cobo Dols M
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2020
País:España
Institución:Instituto de Investigación Biomédica y Sanitaria de Alicante (ISABIAL)
Repositorio:r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
OAI Identifier:oai:isabial.fundanetsuite.com:p6884
Acceso en línea:https://isabial.portalinvestigacion.com/publicaciones6884
Access Level:acceso abierto
Palabra clave:*Lung adenocarcinoma
*metastasis
*non-small cell lung cancer
*overall survival
*prognostic factor
id ES_19bc4e707e85a3bfd07b5d8d3f5bf947
oai_identifier_str oai:isabial.fundanetsuite.com:p6884
network_acronym_str ES
network_name_str España
repository_id_str
spelling Prognostic factors for survival in patients with metastatic lung adenocarcinoma: An analysis of the SEER database.Campos-Balea Bde Castro Carpeño JMassutí BVicente-Baz DPérez Parente DRuiz-Gracia PCrama LCobo Dols M*Lung adenocarcinoma*metastasis*non-small cell lung cancer*overall survival*prognostic factorBACKGROUND: Lung adenocarcinoma (ADC) is the main cause of death related to lung cancer. The aim of this study was to identify poor prognostic factors for overall survival (OS) in patients with stage IV lung ADC in real-world clinical practice. METHODS: Patients were selected from the Surveillance Epidemiology and End Results (SEER) database. Chi-square bivariate analysis was used for the association of binary qualitative variables. A multivariate Cox regression analysis was performed to determine the impact of these prognostic factors on OS. RESULTS: A total of 46 030 patients were included (51.3% men, mean age 67.03 ± 11.6), of whom 41.3% presented with metastases in bone, 28.9% in brain, 17.1% in liver and 31.8% in lung. Patients with liver metastases presented with two or more metastatic sites more frequently than patients without liver metastases (P < 0.001). Male sex (HR 0.78, 95% CI: 0.76-0.80), age = 65 years (HR 1.37, 95% CI: 1.33-1.40), lack of family support (HR 0.80, 95% CI: 0.78-0.81) and presence of liver (HR 1.45, 95% CI: 1.40-1.50), bone (HR 1.21, 95% CI: 1.18-1.24) or brain metastases (HR 1.18, 95% CI: 1.15-1.21) were identified as poor prognostic factors for OS. Patients with liver metastasis showed the highest hazard ratio value (P < 0.001). CONCLUSIONS: The presence of liver metastases was the worst prognostic factor for patients with metastatic lung ADC. This factor should be considered as a stratification factor for future studies evaluating new cancer treatments including immunotherapy. KEY POINTS: SIGNIFICANT FINDINGS OF THE STUDY: Regression analysis identified poor prognostic factors for overall survival. Factors were male sex, age = 65 years, lack of family support and presence of liver, bone and brain metastases. Patients with liver metastasis showed the highest HR (HR = 1.45 95% CI: 1.40-1.50). This study included the highest number of adenocarcinoma patients analyzed so far (N = 46 030). What this study adds The presence of liver metastases should be considered as a stratification factor for future studies evaluating new cancer treatments including immunotherapy.WILEY2020info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://isabial.portalinvestigacion.com/publicaciones6884Thoracic CancerISSN: 17597706ISSNe: 17597714reponame:r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicanteinstname:Instituto de Investigación Biomédica y Sanitaria de Alicante (ISABIAL)Inglésinfo:eu-repo/semantics/openAccessoai:isabial.fundanetsuite.com:p68842026-06-12T10:20:37Z
dc.title.none.fl_str_mv Prognostic factors for survival in patients with metastatic lung adenocarcinoma: An analysis of the SEER database.
title Prognostic factors for survival in patients with metastatic lung adenocarcinoma: An analysis of the SEER database.
spellingShingle Prognostic factors for survival in patients with metastatic lung adenocarcinoma: An analysis of the SEER database.
Campos-Balea B
*Lung adenocarcinoma
*metastasis
*non-small cell lung cancer
*overall survival
*prognostic factor
title_short Prognostic factors for survival in patients with metastatic lung adenocarcinoma: An analysis of the SEER database.
title_full Prognostic factors for survival in patients with metastatic lung adenocarcinoma: An analysis of the SEER database.
title_fullStr Prognostic factors for survival in patients with metastatic lung adenocarcinoma: An analysis of the SEER database.
title_full_unstemmed Prognostic factors for survival in patients with metastatic lung adenocarcinoma: An analysis of the SEER database.
title_sort Prognostic factors for survival in patients with metastatic lung adenocarcinoma: An analysis of the SEER database.
dc.creator.none.fl_str_mv Campos-Balea B
de Castro Carpeño J
Massutí B
Vicente-Baz D
Pérez Parente D
Ruiz-Gracia P
Crama L
Cobo Dols M
author Campos-Balea B
author_facet Campos-Balea B
de Castro Carpeño J
Massutí B
Vicente-Baz D
Pérez Parente D
Ruiz-Gracia P
Crama L
Cobo Dols M
author_role author
author2 de Castro Carpeño J
Massutí B
Vicente-Baz D
Pérez Parente D
Ruiz-Gracia P
Crama L
Cobo Dols M
author2_role author
author
author
author
author
author
author
dc.subject.none.fl_str_mv *Lung adenocarcinoma
*metastasis
*non-small cell lung cancer
*overall survival
*prognostic factor
topic *Lung adenocarcinoma
*metastasis
*non-small cell lung cancer
*overall survival
*prognostic factor
description BACKGROUND: Lung adenocarcinoma (ADC) is the main cause of death related to lung cancer. The aim of this study was to identify poor prognostic factors for overall survival (OS) in patients with stage IV lung ADC in real-world clinical practice. METHODS: Patients were selected from the Surveillance Epidemiology and End Results (SEER) database. Chi-square bivariate analysis was used for the association of binary qualitative variables. A multivariate Cox regression analysis was performed to determine the impact of these prognostic factors on OS. RESULTS: A total of 46 030 patients were included (51.3% men, mean age 67.03 ± 11.6), of whom 41.3% presented with metastases in bone, 28.9% in brain, 17.1% in liver and 31.8% in lung. Patients with liver metastases presented with two or more metastatic sites more frequently than patients without liver metastases (P < 0.001). Male sex (HR 0.78, 95% CI: 0.76-0.80), age = 65 years (HR 1.37, 95% CI: 1.33-1.40), lack of family support (HR 0.80, 95% CI: 0.78-0.81) and presence of liver (HR 1.45, 95% CI: 1.40-1.50), bone (HR 1.21, 95% CI: 1.18-1.24) or brain metastases (HR 1.18, 95% CI: 1.15-1.21) were identified as poor prognostic factors for OS. Patients with liver metastasis showed the highest hazard ratio value (P < 0.001). CONCLUSIONS: The presence of liver metastases was the worst prognostic factor for patients with metastatic lung ADC. This factor should be considered as a stratification factor for future studies evaluating new cancer treatments including immunotherapy. KEY POINTS: SIGNIFICANT FINDINGS OF THE STUDY: Regression analysis identified poor prognostic factors for overall survival. Factors were male sex, age = 65 years, lack of family support and presence of liver, bone and brain metastases. Patients with liver metastasis showed the highest HR (HR = 1.45 95% CI: 1.40-1.50). This study included the highest number of adenocarcinoma patients analyzed so far (N = 46 030). What this study adds The presence of liver metastases should be considered as a stratification factor for future studies evaluating new cancer treatments including immunotherapy.
publishDate 2020
dc.date.none.fl_str_mv 2020
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://isabial.portalinvestigacion.com/publicaciones6884
url https://isabial.portalinvestigacion.com/publicaciones6884
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv WILEY
publisher.none.fl_str_mv WILEY
dc.source.none.fl_str_mv Thoracic Cancer
ISSN: 17597706
ISSNe: 17597714
reponame:r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname:Instituto de Investigación Biomédica y Sanitaria de Alicante (ISABIAL)
instname_str Instituto de Investigación Biomédica y Sanitaria de Alicante (ISABIAL)
reponame_str r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
collection r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869404063537299456
score 15.81155

Similares en LA Referencia